Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8086 to 8100 of 8900 results

  1. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

    This guidance has been updated and replaced by NICE technology appraisal guidance 524.

  2. Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655

  3. Venetoclax for treating chronic lymphocytic leukaemia (TA487)

    This guidance has been updated and replaced by NICE technology appraisal guidance 796.

  4. Mepolizumab for treating severe refractory eosinophilic asthma (TA431)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.

  5. Newer drugs for epilepsy in children (TA79)

    This guideline has been updated and replaced by NICE guideline CG137.

  6. Hearing disability - hearing aids (TA8)

    This guidance has been withdrawn.

  7. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)

    This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.